Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works

Detection and localization of surgically resectable cancers with a multi-analyte blood test

Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · see citing works

OncoKB: A Precision Oncology Knowledge Base

Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,735 · see citing works

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264 · see citing works

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · see citing works

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak‐Jones, C. L., Wolff, D. J., Younes, A., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,054 · see citing works

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal‐Hanjani, M., Constantin, T. P., Salari, R., Quesne, J. P. C. L., Moore, D. A., Veeriah, S., Rosenthal, R., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,880 · see citing works

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,820 · see citing works

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z. G., Geater, S. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,667 · see citing works

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.011 · Cited by 1,495 · see citing works

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · see citing works

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,204 · see citing works

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G. A., Malboeuf, C. M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,156 · see citing works

Direct detection of early-stage cancers using circulating tumor DNA

Phallen, J. A., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J. R., Anagnostou, V., Fiksel, J., Cristiano, S., Papp, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan2415 · Cited by 1,129 · see citing works

Liquid biopsy and minimal residual disease - latest advances and implications for cure

Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110 · see citing works

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,091 · see citing works

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick, D., Zuzarte, P. C., Borgida, A., Wang, T. T., Li, T., et al. (2018) · Nature · doi:10.1038/s41586-018-0703-0 · Cited by 983 · see citing works

Application of Cell-free DNA Analysis to Cancer Treatment

Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 965 · see citing works

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., González-Pérez, A., López-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 836 · see citing works

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E. A., Shen, R., Abida, W. M., Juluru, K., de Bruijn, I., Hou, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0652-7 · Cited by 795 · see citing works

Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · see citing works

Integrating genomic features for non-invasive early lung cancer detection

Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers‐Martin, J. G., Nabet, B. Y., Chen, B., Chaudhuri, A. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2140-0 · Cited by 686 · see citing works

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Rolfo, C. D., Mack, P. C., Scagliotti, G. V., Baas, P., Barlési, F., Bivona, T. G., Herbst, R. S., Mok, T. S. K., Peled, N., Pirker, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.030 · Cited by 665 · see citing works

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E., Colasacco, C., Đačić, S., Hirsch, F. R., Kerr, K. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 660 · see citing works

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0237 · Cited by 623 · see citing works

Circulating tumor DNA and liquid biopsy in oncology

Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600 · see citing works

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 591 · see citing works

Next-generation sequencing in liquid biopsy: cancer screening and early detection

Chen, M., & Zhao, H. (2019) · Human Genomics · doi:10.1186/s40246-019-0220-8 · Cited by 561 · see citing works

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin

Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237802 · Cited by 516 · see citing works

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492 · see citing works

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Thress, K. S., Brant, R., Carr, T. H., Dearden, S. P., Jenkins, S. C., Brown, H. J., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 491 · see citing works

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 487 · see citing works

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487 · see citing works

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel

Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471 · see citing works

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J. R., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., Dilling, T. J., Dobelbower, M. C., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0062 · Cited by 464 · see citing works

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis

Hu, Y., Ulrich, B. C., Supplee, J., Kuang, Y., Lizotte, P. H., Feeney, N. B., Guibert, N. M., Awad, M. M., Wong, K., Janne, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0143 · Cited by 461 · see citing works

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., Cole, R., McWalter, G., Walker, J., Dearden, S., Webster, A., Milenkova, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000263 · Cited by 448 · see citing works

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Goldberg, S. B., Narayan, A., Kole, A. J., Decker, R. H., Teysir, J., Carriero, N. J., Lee, A. Y., Nemati, R., Nath, S. K., Mane, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1341 · Cited by 443 · see citing works

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Shaw, A. T., Solomon, B., Besse, B., Bauer, T. M., Lin, C., Soo, R. A., Riely, G. J., Ou, S. I., Clancy, J. S., Li, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02236 · Cited by 385 · see citing works

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0011-0 · Cited by 366 · see citing works

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0047 · Cited by 348 · see citing works

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. A., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.001 · Cited by 347 · see citing works

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325 · see citing works

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K. A., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 319 · see citing works

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A. M., Galanina, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18613-3 · Cited by 295 · see citing works

Personalized Medicine: Recent Progress in Cancer Therapy

Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. M. R. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 288 · see citing works

Liquid biopsies: Potential and challenges

Heidrich, I., Ačkar, L., Mohammadi, P. M., & Pantel, K. (2020) · International Journal of Cancer · doi:10.1002/ijc.33217 · Cited by 284 · see citing works

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

Paweletz, C. P., Sacher, A. G., Raymond, C. K., Alden, R. S., O’Connell, A., Mach, S. L., Kuang, Y., Gandhi, L., Kirschmeier, P. T., English, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1627-t · Cited by 243 · see citing works

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

Guibert, N. M., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.001 · Cited by 236 · see citing works

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Lin, J. J., Liu, S. V., McCoach, C. E., Zhu, V. W., Tan, A. C., Yoda, S., Peterson, J., Do, A., Prutisto-Chang, K., Dagogo‐Jack, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.015 · Cited by 233 · see citing works

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

Pennell, N. A., Mutebi, A., Zhou, Z., Ricculli, M. L., Tang, W., Wang, H. H., Guérin, A., Arnhart, T., Dalal, A. A., Sasané, M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00356 · Cited by 223 · see citing works

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002

Couraud, S., Vaca-Paniagua, F., Villar, S., Oliver, J., Schuster, T., Blanché, H., Girard, N., Trédaniel, J., Guilleminault, L., Gervais, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3063 · Cited by 215 · see citing works

Guidance for laboratories performing molecular pathology for cancer patients

Cree, I. A., Deans, Z. C., Ligtenberg, M. J. L., Normanno, N., Edsjö, A., Rouleau, É., Solé, F. G., Thunnissen, E., Timens, W., Schuuring, E. M. D., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202404 · Cited by 212 · see citing works

A Comparison of Cell-Free DNA Isolation Kits

Sorber, L., Zwaenepoel, K., Deschoolmeester, V., Roeyen, G., Lardon, F., Rolfo, C. D., & Pauwels, P. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.09.009 · Cited by 207 · see citing works

Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer

Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K., Kozuki, T., Aoe, M., Kiura, K., Ueoka, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1219.11.3 · Cited by 204 · see citing works

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200 · see citing works

Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids

Page, K. M., Guttery, D. S., Zahra, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077963 · Cited by 190 · see citing works

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

Piper‐Vallillo, A. J., Sequist, L. V. D., & Piotrowska, Z. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03123 · Cited by 189 · see citing works

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA

Ooki, A., Maleki, Z., Tsay, J.-C. J., Goparaju, C. M. V., Brait, M., Turaga, N., Nam, H.-S., Rom, W. N., Pass, H. I., Sidransky, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1222 · Cited by 176 · see citing works

Promises, promises, and precision medicine

Joyner, M. J., & Paneth, N. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126119 · Cited by 171 · see citing works

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Mack, P. C., Banks, K. C., Espenschied, C. R., Burich, R. A., Zill, O. A., Lee, C. E., Riess, J. W., Mortimer, S., Talasaz, A. H., Lanman, R. B., et al. (2020) · Cancer · doi:10.1002/cncr.32876 · Cited by 171 · see citing works

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

Jamal‐Hanjani, M., Wilson, G. A., Horswell, S. D., Mitter, R., Sakarya, O., Constantin, T. P., Salari, R., Kırkızlar, E., Sigurjonsson, S., Pelham, R. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw037 · Cited by 170 · see citing works

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

Li, B. T., Jankú, F., Jung, B. K., Hou, C., Madwani, K., Alden, R. S., Razavi, P., Reis-Filho, J. S., Shen, R., Isbell, J. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz046 · Cited by 154 · see citing works

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

Sherwood, J. L., Corcoran, C., Brown, H. J., Sharpe, A. D., Musilová, M., & Kohlmann, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150197 · Cited by 151 · see citing works

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Dagogo‐Jack, I., Rooney, M. M., Lin, J. J., Nagy, R. J., Yeap, B. Y., Hubbeling, H., Chin, E. N., Ackil, J., Farago, A. F., Hata, A. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1436 · Cited by 150 · see citing works

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Shim, J., Kim, H. S., Cha, H., Kim, S., Kim, T. M., Anagnostou, V., Choi, Y., Jung, H. A., Sun, J., Ahn, J. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.004 · Cited by 143 · see citing works

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice

Aggarwal, C., Rolfo, C. D., Oxnard, G. R., Gray, J. E., Sholl, L. M., & Gandara, D. R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0423-x · Cited by 142 · see citing works

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

Rolfo, C. D., Cardona, A. F., Cristofanilli, M., Paz-Ares, L. G., Díaz‐Mochon, J. J., Durán, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102978 · Cited by 139 · see citing works

Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers

Fernández‐Lázaro, D., Garcı́a, J. L., Caballero-García, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10040215 · Cited by 137 · see citing works

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients

Malapelle, U., de-las-Casas, C. M., Rocco, D., Garzón, M., Pisapia, P., Jordana‐Ariza, N., Russo, M., Sgariglia, R., Luca, C. D., Pepe, F., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.8 · Cited by 136 · see citing works

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer

Guibert, N. M., Hu, Y., Feeney, N. B., Kuang, Y., Plagnol, V., Jones, G. R., Howarth, K., Beeler, J. F., Paweletz, C. P., & Oxnard, G. R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy005 · Cited by 135 · see citing works

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Gray, J. E., Okamoto, I., Sriuranpong, V., Vansteenkiste, J., Imamura, F., Lee, J. S., Pang, Y., Cobo, M., Kasahara, K., Cheng, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1126 · Cited by 130 · see citing works

Liquid Biopsy and Lung Cancer

Pisapia, P., Malapelle, U., & Troncone, G. (2018) · Acta Cytologica · doi:10.1159/000492710 · Cited by 117 · see citing works

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 115 · see citing works

Predicting Clinical Outcomes Using Molecular Biomarkers

BURKE, H. B. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s33380 · Cited by 108 · see citing works

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer

Rolfo, C. D., Manca, P., Salgado, R., van Dam, P. A., Dendooven, A., Gandia, J. F., Rutten, A., Lybaert, W., Vermeij, J., Gevaert, T., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000398 · Cited by 102 · see citing works

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Aggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K., Hwang, W., Black, T. A., Yee, S. S., Christensen, T. E., Lariviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102 · see citing works

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol

Sorber, L., Zwaenepoel, K., Jacobs, J., et al. (2019) · Cancers · doi:10.3390/cancers11040458 · Cited by 101 · see citing works

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

Herbst, R. S., Lopes, G., Kowalski, D. M., Nishio, M., Wu, Y., de Castro, G., Baas, P., Kim, D.-W., Gubens, M. A., Cristescu, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.077 · Cited by 101 · see citing works

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

Serrano, M. J., Garrido-Navas, M. C., Díaz‐Mochon, J. J., Cristofanilli, M., Bazo, I. G., Pauwels, P., Malapelle, U., Russo, A., Lorente, J. A., Ruiz-Rodríguez, A. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0466 · Cited by 95 · see citing works

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC

Dagogo‐Jack, I., Rooney, M. M., Nagy, R. J., Lin, J. J., Chin, E. N., Ferris, L. A., Ackil, J., Lennerz, J. K., Lanman, R. B., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.009 · Cited by 93 · see citing works

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions

Villatoro, S., Mayo‐de‐las‐Casas, C., Jordana‐Ariza, N., Viteri, S., Garzón‐Ibáñez, M., Moya‐Horno, I., García‐Peláez, B., González‐Cao, M., Malapelle, U., Balada‐Bel, A., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12574 · Cited by 87 · see citing works

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Zugazagoitia, J., Ramos, I. C., Trigo, J. M., Palka, M., Gómez‐Rueda, A., Lewintre, E. J., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy512 · Cited by 83 · see citing works

MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Guo, R., Offin, M. D., Brannon, A. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2861 · Cited by 79 · see citing works

Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC

Zheng, M.-M., Li, Y.-S., Tu, H., Jiang, B., Yang, J., Zhou, Q. H., Xu, C., Yang, X., & Wu, Y.-L. L. C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.008 · Cited by 75 · see citing works

Understanding EGFR heterogeneity in lung cancer

Passaro, A., Malapelle, U., Re, M. D., Attili, I., Russo, A., Guerini‐Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., Luca, C. D., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000919 · Cited by 74 · see citing works

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

Zhang, Y., Chang, L., Yang, Y., Fang, W., Guan, Y., Wu, A., Hong, S., Zhou, H., Chen, G., Chen, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0581-5 · Cited by 69 · see citing works

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ramalingam, S. S., Gray, J. E., Ohe, Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.076 · Cited by 68 · see citing works

cMET Exon 14 Skipping: From the Structure to the Clinic

Steen, N. V. D., Giovannetti, E., Pauwels, P., Peters, G. J., Hong, D. S., Cappuzzo, F., Hirsch, F. R., & Rolfo, C. D. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.005 · Cited by 65 · see citing works

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

Nacchio, M., Sgariglia, R., Gristina, V., Pisapia, P., Pepe, F., Luca, C. D., Migliatico, I., Clery, E., Greco, L., Vigliar, E., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.19 · Cited by 64 · see citing works

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Zhou, C., Imamura, F., Cheng, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9020 · Cited by 63 · see citing works

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Kim, E. S., Velcheti, V., Mekhail, T. M., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., Hu, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.067 · Cited by 62 · see citing works

Phase II study of tepotinib in NSCLC patients with METex14 mutations.

Paik, P. K., Veillon, R., Cortot, A. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9005 · Cited by 61 · see citing works

Is tissue still the issue in detecting molecular alterations in lung cancer?

Liam, C. K., Mallawathantri, S., & Fong, K. M. (2020) · Respirology · doi:10.1111/resp.13823 · Cited by 61 · see citing works

Liquid biopsy for early stage lung cancer moves ever closer

Rolfo, C. D., & Russo, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0393-z · Cited by 57 · see citing works

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

Remón, J., Lacroix, L., Jovelet, C., Caramella, C., Howarth, K., Plagnol, V., Rosenfeld, N., Morris, C. D., Mezquita, L., Pannet, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00211 · Cited by 54 · see citing works

Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers

Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 54 · see citing works

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Jankú, F., Zhang, S., Waters, J., Liu, L., Huang, H. J., Subbiah, V., Hong, D. S., Karp, D. D., Fu, S., Cai, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0291 · Cited by 53 · see citing works

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

Ricciuti, B., Brambilla, M., Metro, G., Baglivo, S., Matocci, R., Pirro, M., & Chiari, R. (2017) · Medical Oncology · doi:10.1007/s12032-017-0967-5 · Cited by 51 · see citing works

Clinical Relevance of an Amplicon-Based Liquid Biopsy for DetectingALKandROS1Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer

Mezquita, L., Swalduz, A., Jovelet, C., Ortiz‐Cuaran, S., Howarth, K., Planchard, D., Avrillon, V., Recondo, G., Marteau, S., Benítez, J. C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00281 · Cited by 51 · see citing works

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

Wu, Y.-L. L. C., Lee, V. H.-F., Liam, C. K., Lü, S., Park, K., Srimuninnimit, V., Wang, J., Zhou, C., Appius, A., Button, P., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.004 · Cited by 48 · see citing works

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

Koopman, B., van der Wekken, A. J., ter Elst, A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00008 · Cited by 48 · see citing works

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF -Mutant Metastatic Non–Small Cell Lung Cancer

Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M. D., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1037 · Cited by 48 · see citing works

Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions

Sorber, L., Zwaenepoel, K., Jacobs, J., et al. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00442-w · Cited by 47 · see citing works

Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort

Gadgeel, S. M., Mok, T. S. K., Peters, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.079 · Cited by 34 · see citing works

Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies

Shah, M., Takayasu, T., Moghadamtousi, S. Z., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.10.013 · Cited by 33 · see citing works

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

Schwartzberg, L. S., Horinouchi, H., Chan, D. L. H., Chernilo, S., Tsai, M. L., Isla, D., Escriu, C., Bennett, J. P., Clark-Langone, K. M., Svedman, C., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0118-x · Cited by 30 · see citing works

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy

Reclusa, P., Laes, J., Malapelle, U., Valentino, A., Rocco, D., Bazo, I. G., & Rolfo, C. D. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.11.35 · Cited by 30 · see citing works

Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

Garassino, M. C., Gadgeel, S. M., Rodríguez‐Abreu, D., Felip, E., Esteban, E., Speranza, G., Hochmair, M. J., Powell, S. F., Garon, E. B., Hui, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9521 · Cited by 26 · see citing works

Role of liquid biopsy in oncogene-addicted non-small cell lung cancer

Canale, M., Pasini, L., Bronte, G., Delmonte, A., Cravero, P., Crinò, L., & Ulivi, P. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.15 · Cited by 24 · see citing works

Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules

Ye, M., Li, S., Huang, W., Wang, C., Liu, L., Liu, J., Liu, J., Pan, H., Deng, Q., Tang, H., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.09 · Cited by 19 · see citing works

There is still a role for cytology in the ‘liquid biopsy’ era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression

Clery, E., Pisapia, P., Feliciano, S., et al. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204370 · Cited by 18 · see citing works

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Mack, P. C., Redman, M. W., Moon, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9532 · Cited by 11 · see citing works

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy

Reclusa, P., Laes, J., Malapelle, U., et al. (2018) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.21037/25946 · Cited by 9 · see citing works

O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?

Russo, A., McCusker, M. G., Chen, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.088 · Cited by 5 · see citing works

Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)

Garassino, M. C., Paz-Ares, L. G., Hui, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz094.001 · Cited by 3 · see citing works

PD2.01 PD-L1 and Other Potential Predictive Biomarkers Measured in Plasma by RT-PCR in cfRNA and cfDNA to Monitor Clinical Responses in Metastatic Lung Cancer Patients

Raez, L. E., Usher, J. L., Sumarriva, D., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.128 · Cited by 3 · see citing works

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783 · see citing works

Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study

Roberts, H. J., Comeau, H., Klega, K., DuBois, S. G., Lazo de la Vega, L., Ceca, E., Mullen, E. A., Smith, G. A., Tukachinsky, H., Huang, R. S. P., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01125

The future of precision medicine: towards a more predictive personalized medicine

Elemento, O. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20190197 · Cited by 67 · see citing works

HARNESSING THE POWER OF PERSONALIZED MEDICINES: STEPS AND INNOVATIONS

Singhal, P., & Natasha, M. (2023) · Iterative International Publishers eBooks · doi:10.58532/v3bjbt5p5ch3

TRANSFORMING HEALTHCARE WITH PRECISION MEDICINE: UNVEILING THE FUTURE OF PERSONALIZED TREATMENT

Moulik, A. K., Ratnam, R. S., Sriushaswini, B., et al. (2023) · doi:10.53555/jptcp.v30i17.2885

Detecting Personalized Determinants During Drug Treatment from Omics Big Data

Wang, L., Yu, X., Zhang, C., & Zeng, T. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666181106102111 · Cited by 10 · see citing works

Precision (personalized) medicine

Walton, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95274-3.00002-6 · Cited by 3 · see citing works